請用此 Handle URI 來引用此文件: http://hdl.handle.net/11455/40144
標題: Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells
作者: Chen, Chih-Yi
Fang, Hsin-Yuan
Chiou, Shiow-Her
Yi, Shih-En
Huang, Chih-Yang
Chiang, Shu-Fen
Chang, Hui-Wen
Lin, Tze-Yi
Chiang, I-Ping
Chow, Kuan-Chih
關鍵字: bronchial epithelial-cells
hepatocyte growth-factor
nuclear-pore
complex
cancer cells
ovarian-cancer
breast-cancer
factor eef1a2
overexpression
mitochondrial
expression
摘要: By screening mouse monoclonal antibody libraries for Kelch repeats, we serendipitously identified monoclonal antibodies to eukaryotic elongation factor 2 (eEF2). Interestingly, eEF2 was highly expressed in lung adenocarcinoma (LADC), but not in the neighboring non-tumor lung tissue. Normally, eEF2 is involved in the peptidyl-tRNA translocation during protein synthesis. Overexpression of eEF2 would implicate an association with disease progression of LADC. In the present study, we investigated the prognostic significance of eEF2 in patients with LADC. Expression of eEF2 was detected by immunoblotting, immunohistochemistry and confocal immunofluorescence microscopy. Our results show that patients with high eEF2 expression had a significantly higher incidence of early tumor recurrence (67.8% vs 18.2%, P = 0.016), and a significantly worse prognosis (P < 0.001). In an in vitro study, silencing of eEF2 expression increased mitochondrial elongation, cellular autophagy and cisplatin sensitivity. Moreover, eEF2 was sumoylated in LADC cells, and eEF2 sumoylation correlated with drug resistance. These results suggest that eEF2 is an anti-apoptotic marker in LADC. However, biological function and involvement of eEF2 in the disease progression of LADC require further studies. (Cancer Sci 2011; 102: 1582-1589)
URI: http://hdl.handle.net/11455/40144
ISSN: 1347-9032
顯示於類別:生物醫學研究所

文件中的檔案:
沒有與此文件相關的檔案。


在 DSpace 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。